VERAXA Biotech AG (NASDAQ: VRXA) has announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program in collaboration with ATUM, a move that advances the company’s efforts to create more targeted cancer therapies. The collaboration leverages ATUM’s Leap-In Transposase(R) technology to generate stable clonal cell lines that will support IND/CTA-enabling activities and future clinical development, according to a press release.
The announcement follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The cell line development is intended to support chemistry, manufacturing, and controls (CMC) development, including early process, analytical, and formulation development, as well as the production of material for nonclinical studies.
VERAXA’s BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
The importance of this news lies in the potential of VERAXA’s technology to address a key limitation of current T-cell engagers: off-tumor toxicity. By requiring dual tumor antigen binding, the BiTAC platform may offer a safer and more effective treatment option for cancer patients. If successful, this approach could expand the therapeutic index of T-cell engagers, allowing for higher doses and greater efficacy without the severe side effects often seen with traditional therapies.
For the biotech industry, VERAXA’s progress represents a step forward in the development of next-generation antibody-based therapeutics. The company is building a pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative formats, guided by quality-by-design principles. The collaboration with ATUM underscores the importance of robust cell line development in bringing such therapies to the clinic.
Investors and stakeholders should note that the latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. The full press release can be viewed at https://ibn.fm/FCIlk.
